Actively Recruiting
Phase III Study of Eveotox Injection to Evaluate Treatment of Adult Upper Limb Spasticity
Led by JHM BioPharma (Tonghua) Co. , Ltd. · Updated on 2026-09-23
207
Participants Needed
31
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of recombinant botulinum toxin type A Eveotox in adults with upper limb spasticity following stroke. This phase III clinical trial compares Eveotox to a placebo to observe its effects on muscle spasticity and related functional improvements. Participants will receive Eveotox in a double-blind manner during the first treatment cycle, followed by up to three open-label cycles of Eveotox. Those initially assigned to placebo will receive placebo only during the first cycle and then transition to up to three cycles of Eveotox. The study aims to closely monitor the treatments impact over these cycles. During the trial, participants will undergo assessments to evaluate spasticity and functional abilities using scales such as the Modified Ashworth Scale and Disability Assessment Scale. Safety and efficacy will be tracked within four weeks for primary outcomes and up to 52 weeks for secondary measures. Participants will be monitored throughout the study duration, which lasts until January 2028, including safety checks and evaluations of treatment response.
CONDITIONS
Brief Title
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .
Research Team
D
Danhua Lin
L
Lei Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here